[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100233408":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":39,"centralContacts":43,"locations":52,"responsibleParty":70,"collaborators":10,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":10,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":10,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Weill Medical College of Cornell University","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Individuals diagnosed with FRDA",null,"Individuals diagnosed with FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies",[13,14,15,16],"Procedure: Cardiac magnetic resonance imaging (CMR)","Procedure: Exercise-stress test","Procedure: Echocardiogram (ECHO)","Procedure: Cardiac-related blood studies",{"label":18,"type":10,"description":19,"interventionNames":20},"Healthy controls","Individuals without FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies",[13,14,15,16],[22,27,31,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"PROCEDURE","Cardiac magnetic resonance imaging (CMR)","CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called \"contrast\" to get a better picture of the heart.",[18,9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Exercise-stress test","You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.",[18,9],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Echocardiogram (ECHO)","An echocardiogram is an ultrasound of the heart done at rest.",[18,9],{"type":23,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Cardiac-related blood studies","The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).",[18,9],[40],{"name":41,"affiliation":5,"role":42},"Ronald G Crystal, MD","PRINCIPAL_INVESTIGATOR",[44,49],{"name":45,"role":46,"phone":47,"phoneExt":10,"email":48},"Niamh Savage, BS","CONTACT","646-962-5527","nis2049@med.cornell.edu",{"name":50,"role":46,"phone":51,"phoneExt":10,"email":10},"Madeline Galbraith, BS","646-962-2672",[53],{"facility":54,"status":55,"city":56,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Weill Cornell Medicine","RECRUITING","New York","10021","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-74.00597,40.71427,{"lat":64,"lon":63},[67,68],{"name":45,"role":46,"phone":51,"phoneExt":10,"email":48},{"name":50,"role":46,"phone":51,"phoneExt":10,"email":69},"meg4013@med.cornell.edu",{"type":71,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100233408","characterization-of-the-cardiac-phenotype-of-friedreichs-ataxia-frda-100233408",false,"NCT02316314","Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)","Friedreich's Ataxia - Inclusion Criteria:\n\n* Males and females, age 12 to 50\n* Willing and able to provide informed consent (adolescents will need to provide assent and a parent to provide consent)\n* Definitive diagnosis of FRDA, based on clinical phenotype and genotype\n* Left ventricle ejection fraction measured by ECHO of \\>35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF \\\u003C35% will not be required to perform the CPET)\n\nFriedreich's Ataxia - Exclusion Criteria:\n\n* Signs and symptoms of cardiac failure\n* Moderate to severe atrial or ventricular arrythmias\n* History of angina pectoris\n* Implanted pacemaker and\u002F or defibrillator or any other device that would preclude MRI assessment\n* Any form of dialysis; Severe or end-stage CKD (CKD 4 or 5, eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2) without dialysis; eGFR 30 to 40 ml\u002Fmin\u002F1.73 m2 without dialysis; Acute kidney injury (If a recent assessment is not available, then a blood test to assess kidney function will be performed prior to cardiac MRI)\n* Females who are pregnant\n* Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or active enrollment in an investigational medication or device study\n* Unable to undergo cardiac MRI with gadolinium contrast or claustrophobia\n* Clinical history or evidence of Type 1 or Type 2 Diabetes mellitus\n* Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual's ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his\u002F her participation in the study\n\nNormal controls - Inclusion Criteria:\n\n* Males and females, age 12 to 30\n* Willing and able to provide informed consent (Adolescents will need to provide assent and a parent to provide consent)\n* Matched age, gender and ethnicity to the FRDA group\n* Capable of undergoing the various modalities of cardiac assessment\n* Left ventricle ejection fraction measured by ECHO of \\>35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF \\\u003C35% will be withdrawn from the study)\n\nNormal controls - Exclusion Criteria:\n\n* Individuals not deemed in good overall health by the investigator will not be accepted into the study\n* Signs and symptoms of cardiac failure\n* Moderate to severe atrial or ventricular arrhythmias\n* History of angina pectoris\n* Implanted pacemaker and\u002F or defibrillator or any other device that would preclude MRI assessment\n* Any form of dialysis; Severe or end-stage CKD (CKD 4 or 5, eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2) without dialysis; eGFR 30 to 40 ml\u002Fmin\u002F1.73 m2 without dialysis; Acute kidney injury (If a recent assessment is not available, then a blood test to assess kidney function will be performed prior to cardiac MRI)\n* Females who are pregnant or lactating\n* Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or active enrollment in an investigational medication or device study\n* Unable to sit with back support\n* Unable to undergo cardiac MRI with gadolinium contrast or claustrophobia\n* Unable to undergo exercise tests\n* Clinical history or evidence of Type 1 or Type 2 Diabetes mellitus\n* Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual's ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his\u002F her participation in the study",true,"ALL","12 Years","50 Years",{"count":83,"type":84},100,"ESTIMATED","OBSERVATIONAL","Friedreich's ataxia (FRDA) is an autosomal recessive disease characterized by loss of coordination and cardiomyopathy. It is the most common form of inherited ataxia with an incidence in 1\u002F50,000 in the Caucasian population. FRDA is associated with progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems, as well as diabetes and heart disease. The heart disease manifests as cardiomyopathy, and is responsible for approximately 60% of deaths from FRDA. This study is designed to characterize the cardiac manifestations of the disease using exercise, MRI, ECHO and serum parameters, in the context of the neurological disease. In addition, this study will demonstrate that corneal confocal microscopy (CCM) may also provide a biomarker for FRDA.",[88],"Friedreich's Ataxia",[88,90,91,92],"Cardiomyopathy","FRDA","Ataxia","2025-08-18",{"date":95,"type":96},"2025-08-19","ACTUAL",{"date":98,"type":96},"2015-01-15",{"date":100,"type":84},"2026-08",{"name":5,"class":6},1]